• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Phillips-Medisize Builds Hudson, Wisconsin, Manufacturing Center

Phillips-Medisize, a Molex company, started construction of a new state of the art manufacturing facility located in the St. Croix Meadows development in Hudson, Wisconsin.

The company is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments.

According to company officials, this site is expected to support at least 230,000 sq. ft. of manufacturing space for FDA-regulated products. This new Phillips-Medisize facility will be situated on a 34-acre site in St. Croix Meadows development, representing the company’s single largest operation in Wisconsin with opportunity to expand.

“The St. Croix Meadows redevelopment is aimed at transforming the riverfront community,” said Hudson Mayor Rich O'Connor. "By creating employment opportunities with Phillips-Medisize, I hope to encourage young people to stay in Hudson.”

“We are proud to invest in growing Phillips-Medisize’s manufacturing presence in our founding state of Wisconsin,” stated Matt Jennings, CEO and President, Phillips-Medisize.

“Hudson has been home to Phillips-Medisize for the past 36 years, so we are excited to reinforce our commitment to the vibrant community with our St. Croix Meadows facility. We expect to support over 250 employment opportunities for area residents in jobs, ranging from skilled manufacturing to engineering. It also reaffirms our commitment to better serve customers as a global end-to-end provider of innovation, development and manufacturing solutions,” he added.

Founded in the town of Phillips, Wisconsin over five decades ago, Phillips-Medisize currently employs more than 5,500 people at 26 manufacturing sites around the world.

The Phillips-Medisize St. Croix Meadows manufacturing facility will be FDA-registered, adhering to clean room practices, and featuring state-of-the-art equipment to meet quality production standards. Investment in a new facility of this size and scope underscores the company’s commitment to its people, processes and facilities necessary for long-term success.

Exclusive Research